Canaccord Genuity Starts Taysha Gene Therapies at Buy

(marketscreener.com) Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from a Phase 1/2a clinical study of RG6501 , will be presented at the 2023 Retinal Cell and Gene Therapy Innovation Summit, organized by the Foundation Fighting Blindness and the...https//www.marketscreener.com/quote/stock/LINEAGE-CELL-THERAPEUTICS-65218223/news/RG6501-OpRegen-Phase-1-2a-Clinical-Results-to-Be-Presented-at-2023-Retinal-Cell-and-Gene-Therapy-43291452/?utm_medium=RSS&utm_content=20230320

Treatments involve adding a new gene, or using CRISPR to edit one.

in the coming years, scientists hope to end a number of illnesses that have caused misery for generations.

(marketscreener.com) Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from a Phase 1/2a clinical study of RG6501 , will be presented at the 2023 Retinal Cell and Gene Therapy Innovation Summit, organized by the Foundation Fighting Blindness and the...https//www.marketscreener.com/quote/stock/LINEAGE-CELL-THERAPEUTICS-65218223/news/RG6501-OpRegen-Phase-1-2a-Clinical-Results-to-Be-Presented-at-2023-Retinal-Cell-and-Gene-Therapy-43291452/?utm_medium=RSS&utm_content=20230320

ElevateBio, one of the leading biotech companies focused on gene-based therapies has raised a massive $525 million Series C round of financing, more than doubling the company’s $193 million Series B funding which closed last year. This new funding comes from existing investor Matrix Capital M…

A gene-therapy gel designed to treat the rare genetic condition "butterfly disease" showed success in a late-stage trial.

The European Medicines Agency (EMA) said on Friday it plans to issue advice for physicians using Novartis AG’s Zolgensma, calling on them to monitor patients for any liver injury after treatment. The statement follows two deaths due to liver failure after treatment with the gene therapy against spinal muscular atrophy, reported by Novartis in August. […]

People with recessive dystrophic epidermolysis bullosa, a genetic condition that causes widespread skin blistering, have been successfully treated by inserting new collagen genes into their skin

Gossamer Bio is a biotechnology company that specializes in developing and commercializing novel therapies for rare genetic diseases. The company's lead product candidate is GS-102, an investigational gene therapy for Duchenne muscular dystrophy (DMD), which is currently in Phase 3 clinical trials.On Wednesday morning, The Goldman Sachs Group published a research report on Gossamer Bio, in which they decreased the company's price target from $9.00 to $8.00. This change was based on an analysis of the company's financial performance and growth prospects, as well as the competitive landscape in the gene therapy market.The Goldman Sachs Group currently has a buy rating on Gossamer Bio stock, indicating that they believe the stock is undervalued and has potential for significant growth. However, they also noted some risks and uncertainties associated with the company's development and commercialization of GS-102, including regulatory hurdles, competition from other gene therapy companies, and potential safety concerns.Other equities research analysts have also recently weighed in on Gossamer Bio, providing their own price targets and ratings for the stock. For example, JPMorgan Chase has a $9.50 price target and a neutral rating, while Citigroup has a $12.00 price target and a buy rating.Overall, while The Goldman Sachs Group's price target cut may be seen as a negative development for Gossamer Bio investors, it is important to consider the broader context of the company's financial performance and growth prospects, as well as the competitive landscape in the gene therapy market.

(marketscreener.com) NORTH BILLERICA, Mass., Dec. 12, 2022 -- Lantheus Holdings, Inc. , a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, announced a strategic collaboration with SonoThera, Inc., a biotechnology company dedicated...https//www.marketscreener.com/quote/stock/LANTHEUS-HOLDINGS-INC-17053982/news/Lantheus-Grants-Rights-for-the-Use-of-its-Microbubbles-to-SonoThera-for-its-Ultrasound-Guided-Nonvir-42527067/?utm_medium=RSS&utm_content=20221212

(marketscreener.com) U.S. Physical Therapy, Inc. , a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, today announced an acquisition of a two-clinic physical therapy practice.USPH acquired 80% of the equity interests of the physical therapy practice with the practice’s owners retaining 20%. The...https//www.marketscreener.com/quote/stock/U-S-PHYSICAL-THERAPY-IN-11268480/news/U-S-Physical-Therapy-Announces-Acquisition-Of-A-Two-Clinic-Physical-Therapy-Practice-41913873/?utm_medium=RSS&utm_content=20221003

(marketscreener.com) BOSTON, Nov. 02, 2022 -- Decibel Therapeutics , a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the submission of Clinical Trial Applications to the Medicines and Healthcare Products Regulatory Agency in the United Kingdom...https//www.marketscreener.com/quote/stock/DECIBEL-THERAPEUTICS-INC-118907233/news/Decibel-Therapeutics-Announces-Submission-of-Clinical-Trial-Applications-for-Lead-Gene-Therapy-Candi-42176389/?utm_medium=RSS&utm_content=20221102

"We're in the earliest days of the cell and gene therapy revolution," ElevateBio CEO David Hallal told Insider.

(marketscreener.com) Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from a Phase 1/2a clinical study of RG6501 , will be presented at the 2023 Retinal Cell and Gene Therapy Innovation Summit, organized by the Foundation Fighting Blindness and the...https//www.marketscreener.com/quote/stock/LINEAGE-CELL-THERAPEUTICS-65218223/news/RG6501-OpRegen-Phase-1-2a-Clinical-Results-to-Be-Presented-at-2023-Retinal-Cell-and-Gene-Therapy-43291452/?utm_medium=RSS&utm_content=20230320

(marketscreener.com) Precision BioSciences, Inc. a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the H.C. Wainwright Cell Therapy Virtual Conference taking place February 28, 2023.Details for the virtual fireside chat are as...https//www.marketscreener.com/quote/stock/PRECISION-BIOSCIENCES-IN-56171694/news/Precision-BioSciences-to-Participate-in-Upcoming-H-C-Wainwright-Cell-Therapy-Virtual-Conference-43052630/?utm_medium=RSS&utm_content=20230222

(marketscreener.com) SOUTH SAN FRANCISCO, Calif., April 14, 2023 -- Senti Biosciences, Inc. , a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced its participation at the following investor conferences Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing...https//www.marketscreener.com/quote/stock/SENTI-BIOSCIENCES-INC-139248437/news/Senti-Bio-to-Participate-in-Upcoming-Investor-Conferences-43495976/?utm_medium=RSS&utm_content=20230414

One of the major challenges facing gene therapy — a way to treat disease by replacing a patient’s defective genes with healthy ones — is that it is difficult to safely deliver ...

Genopets 24 Hour Trading Volume Tops $606,645.00 (GENE)

Prospects grow cloudy for technology just when it appeared to have turned a corner

(marketscreener.com) Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from a Phase 1/2a clinical study of RG6501 , will be presented at the 2023 Retinal Cell and Gene Therapy Innovation Summit, organized by the Foundation Fighting Blindness and the...https//www.marketscreener.com/quote/stock/LINEAGE-CELL-THERAPEUTICS-65218223/news/RG6501-OpRegen-Phase-1-2a-Clinical-Results-to-Be-Presented-at-2023-Retinal-Cell-and-Gene-Therapy-43291452/?utm_medium=RSS&utm_content=20230320

(marketscreener.com) European Medicines Agency said on Friday it was issuing an alert to healthcare providers over fatal cases of acute liver failure recently reported in patients treated with Novartis AG's gene therapy Zolgensma.https//www.marketscreener.com/quote/stock/NOVARTIS-AG-9364983/news/EU-regulator-issues-alert-over-deaths-related-to-Novartis-gene-therapy-Zolgensma-42728595/?utm_medium=RSS&utm_content=20230113

Genopets 24 Hour Trading Volume Tops $606,645.00 (GENE)

(marketscreener.com) PRESS RELEASE Lysogene announces the request for the opening of a safeguard proceeding Paris, France - 6 December 2022 - Lysogene , a phase 3 gene therapy platform Company targeting central nervous system diseases, today announces the request for the opening of a...https//www.marketscreener.com/quote/stock/LYSOGENE-33951021/news/LYSOGENE-Inside-Information-Operations-of-the-issuer-acquisitions-sales--42490245/?utm_medium=RSS&utm_content=20221206

A gene-therapy gel designed to treat the rare genetic condition "butterfly disease" showed success in a late-stage trial.

(marketscreener.com) Shares of LogicBio Therapeuticsskyrocketed on Monday after Britain's AstraZeneca'ssaid it would buy the U.S.-based gene therapy developerat a rare 660% premium for $68 million. LoigBio's shares, which have traded below $1 since February,were up 637% at $2 before the bell, close to AstraZeneca's offerprice of $2.07 per share. ...https//www.marketscreener.com/quote/stock/ASTRAZENECA-PLC-4000930/news/AstraZeneca-pays-660-premium-for-gene-therapy-firm-LogicBio-41914390/?utm_medium=RSS&utm_content=20221003

A gene therapy that makes use of an unlikely helper, the AIDS virus, gave a working immune system to 48 babies and toddlers who were born without one, doctors reported Tuesday. Results show that all but two of the 50 children who were given the experimental therapy in a study now have healthy germ-fighting abilities...

(marketscreener.com) Precision BioSciences, Inc. a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the H.C. Wainwright Cell Therapy Virtual Conference taking place February 28, 2023.Details for the virtual fireside chat are as...https//www.marketscreener.com/quote/stock/PRECISION-BIOSCIENCES-IN-56171694/news/Precision-BioSciences-to-Participate-in-Upcoming-H-C-Wainwright-Cell-Therapy-Virtual-Conference-43052630/?utm_medium=RSS&utm_content=20230222

A scientific vision for decades, gene therapy is finally becoming more common in the U.S., fueling optimism for the treatment of rare diseases.

Shares of LogicBio Therapeutics skyrocketed on Monday after Britain’s AstraZeneca’s said it would buy the U.S.-based gene therapy developer at a rare 660% premium for $68 million. LoigBio’s shares, which have traded below $1 since February, were up 637% at $2 before the bell, close to AstraZeneca’s offer price of $2.07 per share. LogicBio is […]

(marketscreener.com) SOUTH SAN FRANCISCO, Calif., April 14, 2023 -- Senti Biosciences, Inc. , a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced its participation at the following investor conferences Chardan’s 7th Annual Genetic Medicines and Cell Therapy...https//www.marketscreener.com/quote/stock/SENTI-BIOSCIENCES-INC-139248437/news/Senti-Bio-to-Participate-in-Upcoming-Investor-Conferences-43495978/?utm_medium=RSS&utm_content=20230414

New Technology Platform Replaces Manual Processes and Brings Unmatched Precision and Efficiency to Cell and Gene Therapy Organizations ST. PAUL, Minn. — ScaleReady, a joint venture between Bio-Techne (NASDAQ TECH), Fresenius Kabi and Wilson Wolf, announced today the market launch of the Cue Cell Processing System from Fresenius Kabi, available exclusively from ScaleReady. Cue, an […]

(marketscreener.com) Libmeldy® revenue totaled $5.8M in Q4 2022 and $18.8M for the full year with commercial expansion activities continuing in Europe Clinical Type B meeting with U.S. FDA to take place in early 2023 prior to OTL-200 BLA submission Ended 2022 with approximately $144M in cash and investments and reduced burn rate to support operations into Q2...https//www.marketscreener.com/quote/stock/ORCHARD-THERAPEUTICS-PLC-46901491/news/Orchard-Therapeutics-Highlights-Recent-Progress-Across-HSC-Gene-Therapy-Portfolio-and-Outlines-Key-2-42691446/?utm_medium=RSS&utm_content=20230109

Jordan Janz knew his gamble on an experimental gene therapy for his rare disease might be paying off when he returned to work and a friend sniffed him.“He said, ‘you have a normal smell, you smell good,’” Janz recalled.

Taysha Gene Therapies (NASDAQTSHA) PT Lowered to $5.00

Rejuvenate Bio systemically delivered AAVs (gene therapy delivered via altered virus shells), encoding an inducible OSK system, in 124-week-old mice extends the median remaining lifespan by 109% over wild-type controls and enhances several health parameters. Treated mice lived another 18 weeks, on average, while control mice died in nine weeks. Overall, the treated mice lived ... Read more

(marketscreener.com) Catalent, Inc. , the leader in enabling the development and supply of better treatments for patients worldwide, and Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, today announced the signing of a commercial supply agreement for Catalent to manufacture delandistrogene moxeparvovec , Sarepta’s most...https//www.marketscreener.com/quote/stock/CATALENT-INC-17083784/news/Sarepta-and-Catalent-Expand-Strategic-Manufacturing-Partnership-With-Commercial-Supply-Agreement-for-42666043/?utm_medium=RSS&utm_content=20230105

(marketscreener.com) Global registrational trial expected to commence in the second half of 2023BOSTON and LONDON, Jan. 05, 2023 -- Orchard Therapeutics , a global gene therapy leader, today announced the U.S. Food and Drug Administration has cleared its Investigational New Drug application for OTL-203, a hematopoietic stem cell gene therapy being developed for...https//www.marketscreener.com/quote/stock/ORCHARD-THERAPEUTICS-PLC-46901491/news/Orchard-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-Application-for-OTL-203-in-MPS-IH-42664937/?utm_medium=RSS&utm_content=20230105

(marketscreener.com) - Upstaza™ is the first gene therapy infused directly into the brain for the treatment of AADC deficiency -- MHRA authorization follows recent European Union authorization -- AADC deficiency is a rare, fatal disorder that arrests motor development causing severe disability - SOUTH PLAINFIELD, N.J., Nov. 17, 2022 /PRNewswire/...https//www.marketscreener.com/quote/stock/PTC-THERAPEUTICS-INC-13450034/news/Upstaza-trade-Gene-Therapy-Granted-Marketing-Authorization-for-AADC-deficiency-by-UK-s-MHRA-42344585/?utm_medium=RSS&utm_content=20221117

(marketscreener.com) Ph1/2 AAV5-RPGR (Botaretigene Sparoparvovec) Gene Therapy Trial in RPGR-associatedX-linked Retinitis Pigmentosa Michel Michaelides,1,* Cagri G. Besirli,2,† Yesa Yang,1 Sui Chien Wong,3 Jose Sahel,4 Syed...https//www.marketscreener.com/quote/stock/MEIRAGTX-HOLDINGS-PLC-44154954/news/MeiraGTx-Ph1-2-AAV5-RPGR-Botaretigene-Sparoparvovec-Gene-Therapy-Trial-in-RPGR-associated-X-link-41905067/?utm_medium=RSS&utm_content=20221001

Some people who have long lived with the disease say they worry about living as a healthy person, while others worry about the obstacles to getting treatment.

(marketscreener.com) MALVERN, Pa., Oct. 06, 2022 -- Ocugen, Inc. , a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company will present at two important conferences this month. “I look forward to sharing more about our Modifier Gene Therapy platform—a...https//www.marketscreener.com/quote/stock/OCUGEN-INC-19157135/news/Ocugen-Inc-to-Present-at-Upcoming-Vaccines-Cell-Gene-Therapy-Conferences-41942004/?utm_medium=RSS&utm_content=20221006

(marketscreener.com) SOUTH SAN FRANCISCO, Calif., April 14, 2023 -- Senti Biosciences, Inc. , a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced its participation at the following investor conferences Chardan’s 7th Annual Genetic Medicines and Cell Therapy...https//www.marketscreener.com/quote/stock/SENTI-BIOSCIENCES-INC-139248437/news/Senti-Bio-to-Participate-in-Upcoming-Investor-Conferences-43495978/?utm_medium=RSS&utm_content=20230414

(marketscreener.com) Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from a Phase 1/2a clinical study of RG6501 , will be presented at the 2023 Retinal Cell and Gene Therapy Innovation Summit, organized by the Foundation Fighting Blindness and the...https//www.marketscreener.com/quote/stock/LINEAGE-CELL-THERAPEUTICS-65218223/news/RG6501-OpRegen-Phase-1-2a-Clinical-Results-to-Be-Presented-at-2023-Retinal-Cell-and-Gene-Therapy-43291452/?utm_medium=RSS&utm_content=20230320

(marketscreener.com) SOUTH SAN FRANCISCO, Calif., April 14, 2023 -- Senti Biosciences, Inc. , a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced its participation at the following investor conferences Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing...https//www.marketscreener.com/quote/stock/SENTI-BIOSCIENCES-INC-139248437/news/Senti-Bio-to-Participate-in-Upcoming-Investor-Conferences-43495976/?utm_medium=RSS&utm_content=20230414

The success of gene therapy in treating a fatal form of leukaemia is cause for celebration, but we don't yet know how common such results will be

(marketscreener.com) ROCKVILLE, Md., Nov. 2, 2022 /PRNewswire/ -- REGENXBIO Inc. today announced it will participate in the following upcoming investor conferencesCredit Suisse 31st Annual Healthcare ConferenceDate Tuesday, November 8, 2022Location Terranea Resort, Rancho Palos Verdes, CABarclays Sixth Annual Barclays Gene Editing/Therapy SummitDate...https//www.marketscreener.com/quote/stock/REGENXBIO-INC-23733717/news/REGENXBIO-to-Participate-in-Upcoming-Investor-Conferences-42176491/?utm_medium=RSS&utm_content=20221102

(marketscreener.com) Syncona Ltd on Thursday noted a promising safety profile for a cancer therapy concocted by one investee, and separately announced the completion of an acquisition in the retinal gene therapy space. Syncona said Achilles Therapeutics PLC will next week at an industry conference present clinical data evaluating its T-cell cancer therapy. Updated...https//www.marketscreener.com/quote/stock/SYNCONA-LIMITED-11814171/news/Syncona-s-Achilles-says-cancer-treatment-shows-promise-seals-buy-42450012/?utm_medium=RSS&utm_content=20221201

Deal would boost German company’s drugs pipeline as coronavirus, Roundup lawsuits squeeze results

PTC Therapeutics gene therapy Upstaza for rare neuromuscular disorder gets approval in UK